Cytokinetics (CYTK) Misses Q3 EPS by 35c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts CYTK Hot Sheet
Price: $62.07 -0.39%
Revenue Growth %: +2,004.1%
Financial Fact:
License revenues from related parties: 53.03M
Today's EPS Names:
ATS, SICP, FTCO, More
Revenue Growth %: +2,004.1%
Financial Fact:
License revenues from related parties: 53.03M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q3 EPS of ($1.52), $0.35 worse than the analyst estimate of ($1.17). Revenue for the quarter came in at $2.52 million versus the consensus estimate of $3.16 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- CPS Technologies (CPSH) Reports In-Line Q3 EPS
- Uber Q3 profit, revenue beat estimates as gross bookings jump 20%
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
